NCT07468500
Real World Adherence of PCSK9 Targeted Therapy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 8 words Show 6 more changesShow less
- Completed without a posted recruiting period
- Final enrollment: 942 participants (planned 3600)
- Primary completion date changed from estimate of Jul 30, 2026 to May 29, 2026
- Study sites: 0 to 1
- Start date changed from estimate of Mar 30, 2026 to Feb 10, 2026
- Secondary endpoints: details revised at 1 of 4 entries
- Notable Eligibility criteria shortened, about 38 words
- Start date: Mar 15, 2026 to Mar 30, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Medication adherence at 12 months : proportion of days covered (PDC) within a period that the patient is persistent
Timeframe: 12 months
Secondary (4)
Proportion of patients with good adherence
Number of patients by demographic category
Time to discontinuation
Proportion of patients receiving LLTs
Arms and interventions
exposure group
patients who initiated inclisiran as their first treatment
control group
patients who initiated evolocumab as their first treatment
Sites
1 site in 1 country
- Novartis Investigative SiteTokyo, Japan